GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Lilly Collaboration Accelerates RyboDyn's Dark Proteome Targets Toward First-in-Class Therapies SAN DIEGO, /PRNewswire/ -- RyboDyn, Inc., a biotechnology company pioneering first-in-class ...

A large, multicountry European study finds that adults with type 2 diabetes who start empagliflozin experience no increased ...

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...

Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

WEDNESDAY, June 18, 2025 (HealthDay News) — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for ...

Sitting at her perch from the “Massachusetts Pavilion,” Gov. Maura Healey briefly gestured Tuesday to nearby competitors with flashy booths set up at the BIO International Convention, ...

Deal would add a potential treatment for cardiovascular disease to Eli Lilly's portfolio. The food giant says it will remove the dyes from products including Jell-O, Kool-Aid and Crystal Light before ...

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...